- Home
- NB vs ALXO Comparison
NB vs ALXO Comparison
Compare NB & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NB
- ALXO
- Stock Information
- Founded
- NB 1987
- ALXO 2015
- Country
- NB United States
- ALXO United States
- Employees
- NB N/A
- ALXO N/A
- Industry
- NB Metal Mining
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- NB Basic Materials
- ALXO Health Care
- Exchange
- NB Nasdaq
- ALXO Nasdaq
- Market Cap
- NB 65.9M
- ALXO 76.5M
- IPO Year
- NB N/A
- ALXO 2020
- Fundamental
- Price
- NB $1.62
- ALXO $1.74
- Analyst Decision
- NB Strong Buy
- ALXO Buy
- Analyst Count
- NB 2
- ALXO 6
- Target Price
- NB $3.63
- ALXO $11.00
- AVG Volume (30 Days)
- NB 129.8K
- ALXO 1.1M
- Earning Date
- NB 02-11-2025
- ALXO 03-06-2025
- Dividend Yield
- NB N/A
- ALXO N/A
- EPS Growth
- NB N/A
- ALXO N/A
- EPS
- NB N/A
- ALXO N/A
- Revenue
- NB N/A
- ALXO N/A
- Revenue This Year
- NB N/A
- ALXO N/A
- Revenue Next Year
- NB N/A
- ALXO N/A
- P/E Ratio
- NB N/A
- ALXO N/A
- Revenue Growth
- NB N/A
- ALXO N/A
- 52 Week Low
- NB $1.27
- ALXO $1.19
- 52 Week High
- NB $4.00
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- NB 57.44
- ALXO 53.13
- Support Level
- NB $1.49
- ALXO $1.56
- Resistance Level
- NB $1.65
- ALXO $1.94
- Average True Range (ATR)
- NB 0.12
- ALXO 0.16
- MACD
- NB 0.01
- ALXO -0.01
- Stochastic Oscillator
- NB 84.62
- ALXO 50.00
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.